Head and Neck Cancer

2017 OUTCOMES REPORT

With patient-centered care, Inova Schar Cancer Institute brings new hope and possibilities to those facing head and neck cancer.

Multidisciplinary Clinic
Led by world-class medical oncologist, John Deeken, MD, the Head and Neck Cancer Clinic is held the first Tuesday and third Thursday of each month. The Head and Neck Tumor Board Conference meets twice monthly for case presentation and multidisciplinary discussion.

Screening
In collaboration with Inova Schar Cancer Institute, each Inova hospital supported a Head and Neck Cancer Screening at no cost to attendees. Volunteers included four head and neck surgeons, one radiation oncologist and 10 support staff including nurses, therapists, cancer registrars and Schar cancer center directors. Physician volunteers included: Head and Neck Surgeons; Sarah Blank, MD; Alex Cheng, MD; Patty Lee, MD; Ashley O’Reilly, MD; and Radiation Oncologist; Lonika Majithia, MD.

A total of 56 patients were provided a basic head and neck screening where physicians looked into mouths, ears and nose, felt for lymph nodes, and visually inspected the head and neck region. Physicians documented normal and abnormal findings on a screening sheet given to the patient. Further evaluation was recommended for 28 attendees and a list of physician practices was provided to those patients.

A six-month follow-up showed that 16 patients had seen their physician or were scheduled to see a physician, four had not seen a physician yet, and with further outreach, eight were unable to be contacted.

Community Health Needs Assessment
The most recent hospital Community Needs Assessment revealed that Prince William County, located west of Inova’s primary service area, had a cancer mortality rate higher than the state of Virginia average for oral cavity cancers. Targeted marketing of the Head and Neck Cancer Screening reached Prince William County and additional communities.

*Source: Virginia Department of Health, 2012

Our Physicians

Head and Neck Cancer Team

John Deeken, MD  William Purkert, MD  Gopal Bajaj, MD
Medical Oncologist  Surgeon  Radiation Oncologist

The 2017 outcomes presented are specific to Inova Schar Cancer Institute’s Head and Neck Cancer program and related support services.
Head and Neck Cancers: New Cases

The following Head and Neck Cancer trials were available to patients at the Inova Schar Cancer Institute in 2017. Note: Some trials as indicated are now closed to enrollment.

Open Trials

RTOG 3504 Randomized Phase III trial of Cisplatin-based Chemoradiotherapy (CRT) +/- Nivolumab (Anti-PD-1) in patients with intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma (with lead In component). (Pt: Deeken)

RTOG 1008 Randomized Phase II/III study of adjuvant concurrent radiation and chemotherapy versus radiation alone in resected high-risk malignant salivary gland tumors. (Pt: Deeken)

A091404 Phase II Study of Enzalutamide (NSC# 766085) for patients with androgen receptor positive salivary cancers. (Pt: Deeken)

Temporarily Closed to Enrollment

RTOG1216 Randomized Phase II/III trial of surgery and post-operative radiation delivered with concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for high-risk squamous cell cancer of the head and neck. (Pt: Deeken)

Closed to Enrollment

MK-3475 A Study of Pembrolizumab for first line treatment of recurrent or metastatic squamous cell cancer of the head and neck (MK-3475-048/KEYNOTE-048). (Pt: Deeken)

BMS CA209651 An open label, randomized, two arm Phase III study of Nivolumab in combination with Ipilimumab versus extreme study regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first line therapy in recurrent or metastatic squamous cell carcinoma of the head and neck. (Pt: Deeken)

E3311 Phase II randomized trial of transoral surgical resection followed by low-dose or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer. (Pt: Deeken)